INCB123667 + palbociclib

INCB123667 + palbociclib is an experimental combination therapy consisting of INCB123667, a selective inhibitor of cyclin-dependent kinase 2 (CDK2), and palbociclib, an approved oral inhibitor of cyclin-dependent kinases 4/6 (CDK4/6). This combination is being investigated in clinical trials for the treatment of advanced solid tumors, including hormone receptor-positive (HR+), HER2-negative and HER2-positive breast cancer, as well as other types of solid tumors such as CCNE1+ ovarian, fallopian, and peritoneal cancers. INCB123667 is being developed to target tumors with dysregulated cell cycle machinery through inhibition of CDK2, while palbociclib blocks CDK4/6 activity, together aiming to achieve a broader and potentially synergistic suppression of tumor cell proliferation. The combination is intended to overcome resistance mechanisms that may arise from single-agent CDK4/6 inhibition[1][5].

Other names

INCB123667INCB-123667INCB 123667PD-0332991PD0332991PD 0332991